Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study

Table 1 Clinicopathological features, PDL1, FOXP1, STAT3 expression and outcome of our patients

Parameters	All studied patients (N = 50)		Parameters	All studied patients (N = 50)
Parameters	No.	%	Parameters	No.	%
Age			PD-L1
< 40 years	8	16%	Low	31	62%
40–60 years	20	40%	High	19	38%
61–74 years	17	34%
≥ 75 years	5	10%
Sex			FOXP-1
Male	31	62%	Low	29	58%
Female	19	38%	High	21	42%
History of Hepatitis B			STAT-3
Absent	42	84%	Low	27	54%
Present	8	16%	High	23	46%
B symptoms			Received regimen
Absent	31	62%	No	2	4%
Present	19	38%	CVP	7	14%
Fever			RCVP	8	16%
Absent	31	62%	CHOP	18	36%
Present	19	38%	RCHOP	15	30%
Weight loss			Number of cycles
Absent	31	62%	4 cycles	7	14%
Present	19	38%	4–6 cycles	23	46%
Night sweating			6–8 cycles	20	40%
Absent	31	62%
Present	19	38%
ECOG Ps			Involved field RT
ECOG 1	37	74%	No	28	56%
ECOG 2–4	13	26%	Yes	22	44%
Bulky nodes			Dose
Absent	23	46%	No	28	56%
Present	27	54%	30Gy	9	18%
Extranodal involvement			36Gy	6	12%
Absent	23	46%	40Gy	7	14%
Present	27	54%
Bone marrow involvement			Response
Absent	31	62%	PD	3	6%
Present	19	38%	SD	2	4%
LDH			PR	3	6%
≤ ULN	20	40%	CR	42	84%
> ULN - <3xULN	14	28%	NR	5	10%
> 3xULN	16	32%	OAR	45	90%
Stage			Follow-up months
Stage I	11	22%	Mean ± SD	28.82	±8.98
Stage II	16	32%	Median Range	35	(10–36)
Stage III	13	26%	Relapse	(N = 42)
Stage IV	10	20%	Absent	28	66.7%
IPI risk group			Present	14	34%
Low	22	44%	Mortality
Low – Intermediate	5	10%	Alive	33	66%
High – Intermediate	7	14%	Died	17	34%
High	16	32%

ISSN: 2520-8454